BioTrillion

On a mission is to empower 1 billion people with access to real-time and longitudinal health insights by developing technology that allows users to gain insights into their heart, brain, and lungs.

Global (world)

use gpt ***********

Traditional disease detection & drug development are limited by physical Medical settings with assessments that are qualitative, slow, expensive.

Healthcare Problem #1: Temporal
When… do diseases actually reveal themselves? Less than 1% of our time is spent in a Medical setting, yet 99% of “solutions” exist there. We must think about that other 99% of time – as healthCare-as-a-Continuum.

Healthcare Problem #2: Physical
Where… do diseases actually reveal themselves? Diseases express signs via physical molecular modalities (70% of clinician decision making). But, diseases also express via physiologic modalities too. Many of these signs can be optically measured as biometrics (“Digital Biomarkers”).

Our mission is to enable 1 billion ordinary people with the ability to measure extraordinary health insights – using only their existing smartphone.

We’re developing deep learning powered computer vision software.
Leveraging continual advancements in smartphone camera hardware.
To visually and quantitatively measure multiple spatiotemporal features in the eyes, face, hands (“life data”) that are early (often pre-symptomatic) signs of diseases.— from only a 5 second user face scan (a “Healthy Selfie”).

Clinically validating and converting these features into multiple digital biomarkers targeting multiple diseases with statistically synergistic increases in clinical sensitivity and specificity.

Currently 5 digital biomarkers:
1. “fHR”, 2. fSpO2, 3. “pxReflex” 4. “hTremor,” 5. “iTremor.”

Applications span Brain, Heart, Lung diseases detection and drugs development.

Enabling anyone, anytime, anywhere to download our digital biomarker software as a mobile app, which can:
scale to over 1B People (only requiring a smartphone);
monetize with:
Pharma (decentralized and accelerated clinical trials); Providers (Telehealth 2.0; remote disease progression monitoring); Payors (earlier disease detection and lowered costs).

EX-HEALTHCARE MARKETS*
TAM: $1B+/yr

Pharma* (Decentralized Trials for New Therapeutics)
TAM: $1B+/yr
Recruitment: Faster and Cheaper Triaging of Subjects – from Home
Clinical Trials: PK/PD and Objective Safety and Efficacy Endpoint Measures

Providers (Telehealth 2.0)
TAM: $20B+/yr
Remote Monitoring of Diseases
(Pre-Dx early disease detection and Post-Dx disease progression tracking)

Payors
TAM: $10B+/yr
Earlier Disease Detection, Risk Monitoring, Wellness
(Pre-Dx disease prevention)

Our BioEngine4D technology platform is both vertically and horizontally scalable. It will be commercially deployed in a multi-market staggered GTM approach, progressing across each stakeholder in the healthcare continuum. Initially with clinician intermediaries (B2B2C), then directly to consumers (B2C), as validation and familiarity increases. Applications in non-HC markets too.

At its most fundamental level, our technology enables users to measure multiple disease digital biomarkers – using only a smartphone: Anyone, Anywhere, Anytime. Our technology has utility in a plethora of markets, thus we’ve kept our pricing model simple and scalable.
-Per Scan
-Per Month (SaaS)
-Per License (Industry exclusive; finite period)

We believe the Digital Biomarker industry is still in its 1st innings, but with exponentiating tools like deep learning, new markets will grow rapidly.

The digital biomarker vertical of healthcare today is analogous to the Internet circa 1996 – we’re only in its 1st innings.

BioTrillion is now in the top Google Search results for:
“Digital Biomarker Startups.”

Potential Comps
• Verily Life Sciences (subsidiary of Google): many healthcare projects with a focus area in digital biomarkers; however, largely uses internally developed hardware (https://verily.com/)
• Evidation Health: an online engine to measure + analyze behavioral data points from wearable technology (https://evidation.com/)
• Mindstrong Health: a mobile app platform to measure digital biomarkers for behavioral health (https://mindstrong.com/)

We all tend to "discount" that which we do not "count."

BioTrillion was architected from Day 1 for mass scale-from-synergies.
Healthcare needs to advance from qualitative to quantitative to computable to scalable.

Traditional Approach:
For single Disease X, how would we require “Clinicians” to physically measure only its biomarker(s)?

BioTrillion Approach:
What anatomic features could 1 billion “Consumers” digitally self measure, right now? What multitude of diseases do they best biomark to?

BioTrillion’s goals are a moonshot and represents a compelling investment opportunity with a massively asymmetric reward-risk profile. The following represent what we believe to be the greatest risks; along with their mitigants:

-Financial
Risks: Delayed Pharma and Payor revenue partnerships while cash burn and R&D costs continue
Mitigants: Conservative burn; Founder has chosen to forego a salary from inception to date. Additional investments and non-dilutive grant funding interest.


-Technical
Risks: Low reproducibility and accuracy of digital biomarkers.
Mitigants: Approaching with multiple bleeding edge methods for Comuter Vision, both Classical-based and/or AI-based.

-Clinical
Risks: Inability of digital biomarkers to detect disease targets with high sentitivity and specificity.

Mitigants: R&D is premised on causal physiologic pathways and we’ve already achieved the first steps of validation by being able to detect drug use. Each unique Digital Biomarker is akin to a drug in Biotech’s pipeline – each with multiple multi-billion-dollar markets when used individually and synergistic confidence levels when used together.

-Go-to-Market

Risks: Ineffective go-to-market strategy and poor interest + engagement from Consumers.

Mitigants: Strategic and financial decision to focus on a post-diagnosis solution for Pharma first, to provide validation for Providers and Payors for a broader solution. Increase in breadth of disease targets over time, branching out from Alzheimer’s to other neurological + dermatological conditions to attract a wider/younger user base.


-Competitive

Risks: Competitors with first-mover advantage, existing market share, and higher brand recognition (Apple, Google, Amazon).

Mitigants: Focus on Alzheimer’s, for which a major need for novel and innovative solutions remains unmet. Use of the optical modality (camera) of the smartphone continues to be highly unutilized for health applications.

We are fortunate to have been accepted into and greatly assisted by our accelerator programs: IBM, Microsoft, NVIDIA, and Amazon.

IBM and NVIDIA, especially, have expressed tremendous bullishness in BioTrillion, and as a result have mobilized resources to help our path to market.

NVIDIA recently highlighted us in an article saying: “Herbst [Head of NVIDIA’s Business Development] calls out BioTrillion as one to watch.”

"*Selected (from 300+ applicants) by HLTH (a leading Health Technology industry conference) for their Startup Spotlight Presentation [2018]
*Selected (from 700+ applicants) as one of the final eight presenters at HIMSS19 VentureConnect Pitch competition for the “most fundable startup” [2019]
*HLTH Top 5% selected for Startup Spotlight Presentation [2019]
*Selected and invited to present at additional conferences including:
AI Innovation in Life Sciences Summit West, Silicon Valley Science and Technology Forum, AI-Med, KNect365 Life Sciences, Digital Health 4 Pharma, AI Innovation in Life Sciences East, and others [2018 throughout 2022].
*Finalist at ADDF Startup Pitch Competition [2021].
*Finalist at Medtech Innovator Startup Pitch Competition [2021].
*Finalist at VA Startup Pitch Competition [2021].
*Winner of Unicorn Events for North America [2022]; finalist [2021].

Yes

Our 5 digital biomarkers are backed by a robust IP portfolio of 7 utility patents and 2 provisional patents pending, globally – focused on AI software enabling multimodal sensors in smart devices as digital biomarkers to detect key diseases, disorders, drug effects, and drug-use.

Clinical Trials:
-For BioEngine4D current portfolio of 2 digital biomarkers (pxReflex & hTremor) in: 1 acute indication (drug endpoints measures) + 1 chronic indication (Alzheimer’s detection).

Launch and Commercialization:
-Additional hires: Clinical Operations, 3x Business Development.
- Mobile app finalization for scale and backend/DevOps.
-Accelerate R&D to Expand Portfolio of More Digital Biomarkers.
-Adds to team in Computer Vision and Medical to extend existing digital biomarkers into more diseases, based on adjacent features in eyes and face.
-We can reach organic FCF+ without requiring any post Series-A financing.

We are raising a $7.8M Series-A in 2022.

We've previously raised a $2.2M seed round, via SAFE instrument ($35M cap, 20% discount) with investors from marques institutions across the health and tech domains.